- Home
- PPBT vs ALZN Comparison
PPBT vs ALZN Comparison
Compare PPBT & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- ALZN
- Stock Information
- Founded
- PPBT 2010
- ALZN 2016
- Country
- PPBT Israel
- ALZN United States
- Employees
- PPBT N/A
- ALZN N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- PPBT Health Care
- ALZN Health Care
- Exchange
- PPBT Nasdaq
- ALZN Nasdaq
- Market Cap
- PPBT 7.1M
- ALZN 6.1M
- IPO Year
- PPBT N/A
- ALZN 2021
- Fundamental
- Price
- PPBT $2.73
- ALZN $0.70
- Analyst Decision
- PPBT Strong Buy
- ALZN Strong Buy
- Analyst Count
- PPBT 1
- ALZN 1
- Target Price
- PPBT $33.00
- ALZN $20.00
- AVG Volume (30 Days)
- PPBT 16.2K
- ALZN 124.9K
- Earning Date
- PPBT 05-20-2025
- ALZN 03-10-2025
- Dividend Yield
- PPBT N/A
- ALZN N/A
- EPS Growth
- PPBT N/A
- ALZN N/A
- EPS
- PPBT N/A
- ALZN N/A
- Revenue
- PPBT N/A
- ALZN N/A
- Revenue This Year
- PPBT N/A
- ALZN $322.64
- Revenue Next Year
- PPBT N/A
- ALZN N/A
- P/E Ratio
- PPBT N/A
- ALZN N/A
- Revenue Growth
- PPBT N/A
- ALZN N/A
- 52 Week Low
- PPBT $2.00
- ALZN $0.64
- 52 Week High
- PPBT $20.60
- ALZN $15.06
- Technical
- Relative Strength Index (RSI)
- PPBT 51.95
- ALZN 35.54
- Support Level
- PPBT $2.67
- ALZN $0.67
- Resistance Level
- PPBT $2.75
- ALZN $0.71
- Average True Range (ATR)
- PPBT 0.21
- ALZN 0.07
- MACD
- PPBT 0.04
- ALZN -0.02
- Stochastic Oscillator
- PPBT 67.19
- ALZN 10.43
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.